Tarsus Pharmaceuticals, Inc. - TARS
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TANG CAPITAL MANAGEMENT, LLC | 2.8% | 1,188,624 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | KEVIN TANG | 2.8% | 1,188,624 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TANG CAPITAL PARTNERS, LP | 0.81% | 345,686 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TANG CAPITAL PARTNERS INTERNATIONAL, LP | 1.85% | 784,938 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TANG CAPITAL PARTNERS III, INC | 0.1% | 43,500 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TANG CAPITAL PARTNERS IV, INC | 0.04% | 14,500 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Deep Track Capital, LP | 7.11% | 3,000,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 7.11% | 3,000,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | David Kroin | 7.11% | 3,000,000 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.